.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
CRASH-3 was a large randomized trial evaluating tranexamic acid in adults with acute traumatic brain injury. The overall findings did not show a universal mortality benefit across all patients, but the study identified a more favorable effect among patients with less severe injury when treatment was given early. Importantly, tranexamic acid did not appear to produce a major excess of vascular occlusive complications in the trial population. For trauma teams, the clinical message is one of timing and patient selection rather than indiscriminate administration. Early treatment may be most useful before irreversible bleeding-related neurological injury develops, particularly in patients with mild-to-moderate traumatic brain injury. The trial also demonstrates why treatment effects in trauma can vary according to baseline severity and time from injury. Tranexamic acid should therefore be considered within the broader trauma protocol, alongside hemorrhage control, neuroimaging, airway management and definitive neurosurgical or critical-care decisions. CRASH-3 strengthened the evidence base for early antifibrinolytic therapy while illustrating the importance of applying trial findings to the right patient population.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
CRASH-3 was a large randomized trial evaluating tranexamic acid in adults with acute traumatic brain injury. The overall findings did not show a universal mortality benefit across all patients, but the study identified a more favorable effect among patients with less severe injury when treatment was given early. Importantly, tranexamic acid did not appear to produce a major excess of vascular occlusive complications in the trial population. For trauma teams, the clinical message is one of timing and patient selection rather than indiscriminate administration. Early treatment may be most useful before irreversible bleeding-related neurological injury develops, particularly in patients with mild-to-moderate traumatic brain injury. The trial also demonstrates why treatment effects in trauma can vary according to baseline severity and time from injury. Tranexamic acid should therefore be considered within the broader trauma protocol, alongside hemorrhage control, neuroimaging, airway management and definitive neurosurgical or critical-care decisions. CRASH-3 strengthened the evidence base for early antifibrinolytic therapy while illustrating the importance of applying trial findings to the right patient population.
Yesterday
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
